GlobeNewsWire
20 Jan 2026, 21:03 UTC · 41w ago
Verdict
Headline takes no side. We score MREO −1.00 across four claims — strongly bearish.
−1.00strongly bearish
More negative than 99% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
Mereo BioPharma announced that both Phase 3 studies for setrusumab failed to achieve statistical significance on their primary endpoints of reduction in annualized clinical fracture rate.
More negative than 99% of claims this week
On the news of the Phase 3 results, Mereo's stock price fell 87.64% to close at $0.28 per share on December 29, 2025.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Search tags
More negative than 99% of claims this week
Pomerantz LLP is investigating claims on behalf of Mereo investors regarding whether the company and certain officers engaged in securities fraud or unlawful business practices.
More negative than 91% of claims this week
Both Phase 3 studies for setrusumab achieved their secondary endpoints with strong statistical significance, showing improvements in bone mineral density against comparators with no change in safety profile.
So whatPositive secondary endpoints and a clean safety profile provide marginal residual value, potentially supporting alternative development paths or partnership opportunities despite the primary failure.
More positive than 47% of claims this week
Which stocks this story touches
More negative than 99% of ticker scores this week
The company's stock plummeted over 87% following failed Phase 3 studies and is now the subject of a securities fraud investigation.
More negative than 81% of ticker scores this week
The company is being investigated by a law firm on behalf of investors for potential securities fraud or unlawful business practices.
More negative than 81% of ticker scores this week
The company is being investigated by a law firm on behalf of investors for potential securities fraud or unlawful business practices.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
The Motley Fool
2h ago
−48.5%
Price agrees with the score
$0.2910 vs $0.5651 close before publication (Jan 20) · not market-adjusted
MREO chart →
